Minovia Therapeutics secures two new U.S. patents for its **Mitochondrial Augmentation Therapy** platform. The patents expand intellectual property protections for its approach to enhancing mitochondrial function. The company continues to develop therapies targeting cellular energy deficits.
Minovia Therapeutics secures FDA Fast Track designation for its experimental drug **MNV-201**, targeting **myelodysplastic syndrome**. The designation accelerates development and review for therapies addressing unmet medical needs in blood disorders. The company now advances clinical trials under the expedited pathway.
Minovia Therapeutics Ltd. secures an $180 million pre-money equity valuation through a definitive business combination agreement with Launch One Acquisition Corp. The deal combines Minovia’s biotech assets with Launch One’s SPAC structure to pursue a public listing. Minovia focuses on developing therapies in oncology and autoimmune diseases.
Launch One Acquisition Corp. I enables investors to trade its Class A ordinary shares and warrants separately starting September 3, 2024. This move follows its initial public offering, where units combining shares and warrants were sold. The change allows greater flexibility for holders of the units.
Launch One Acquisition Corp. raises **$230 million** through a **$10-per-unit IPO** of **23 million units**. The proceeds fund future acquisitions in its target sectors. The company operates as a special purpose acquisition vehicle (SPAC) to merge with and take public private businesses.